Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting

Core Insights - Cogent Biosciences announced additional clinical results from the SUMMIT trial for bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM), showing significant improvements across primary and secondary endpoints [1][2] Group 1: Clinical Results - Bezuclastinib demonstrated a mean change of -32.0 points in Total Symptom Score (TSS) at 48 weeks, indicating a 56% relative improvement from baseline [5][6] - 99% of patients achieved over 50% reduction in serum tryptase levels, with 83% normalizing their levels [6][11] - Significant improvements were observed across various symptoms, including a 65% reduction in dermatologic symptoms and a 53.6% reduction in neurocognitive symptoms [4][11] Group 2: Safety and Tolerability - Bezuclastinib exhibited a favorable safety and tolerability profile, supporting its potential for chronic use in NonAdvSM patients [7][11] Group 3: Market Position and Future Potential - The company believes bezuclastinib has the potential to become the preferred standard of care for NonAdvSM patients due to its rapid and meaningful symptom improvement [2][10] - The treatment is positioned as the first disease-modifying agent for NonAdvSM, with strong evidence correlating serum tryptase reduction with symptomatic improvement [5][11] Group 4: Inducement Grants - Cogent announced inducement equity awards to three new employees, including nonqualified options to purchase 24,000 shares and 21,000 restricted stock units (RSUs) [8]